This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Can Pharmacy Services Drive CVS Health's (CVS) Q4 Earnings?
by Zacks Equity Research
CVS Health's (CVS) Q4 earnings are expected to gain from strength in the Pharmacy Services segment.
Markets Deeper in the Red, Q4 Reports Stay Healthy
by Mark Vickery
Keeping with Q4 earnings results, here are 4 leaders in their respective spaces and how well they have performed relative to expectations.
Aetna (AET) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Aetna's (AET) results reflected lower revenues, increased investment spending, decline in membership.
Anthem (ANTM) Q4 Earnings: Is a Beat in Store for the Stock?
by Zacks Equity Research
Anthem's (ANTM) fourth-quarter earnings are likely to gain from top-line appreciation driven by enrollment growth.
Will Lower Revenues Weigh on Aetna's (AET) Q4 Earnings?
by Zacks Equity Research
Aetna's (AET) Q4 earnings are likely to be adversely impacted by lower revenues from the healthcare segment and a decline in membership.
AET vs. HCA: Which Stock is Poised for Better Q4 Earnings?
by Zacks Equity Research
Let us try to find out which stock between Aetna (AET) and HCA Healthcare (HCA) is better positioned for an earnings beat in the fourth quarter
Zacks Industry Outlook Highlights: Aetna, Humana, Cigna and Anthem
by Zacks Equity Research
Zacks Industry Outlook Highlights: Aetna, Humana, Cigna and Anthem
Will HCA Healthcare's (HCA) Earnings Beat Estimates in Q4?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter results are expected to be driven by higher admissions
Disruptive Forces to Keep Health Insurers on Their Toes
by Zacks Equity Research
The year 2018 should be lined with continued policy changes and ongoing uncertainty for health insurers.
Zacks Industry Outlook Highlights: Aetna, Cigna, UnitedHealth and CVS Health
by Zacks Equity Research
Zacks Industry Outlook Highlights: Aetna, Cigna, UnitedHealth and CVS Health
ANTM or AET: Which is a Better Pick in Booming HMO Industry?
by Zacks Equity Research
On a comparative analysis, we try and find out which stock - Anthem (ANTM) or Aetna (AET) - is better positioned in terms of fundamentals.
CVS Health's (CVS) Outlook for 2018 Cheered by Investors
by Zacks Equity Research
CVS Health (CVS) to witness increased cash flow of around $1.2 billion in 2018, courtesy the latest US Tax legislation.
Implied Volatility Surging for Aetna (AET) Stock Options
by Zacks Equity Research
Aetna (AET) needs investors to pay close attention to the stock based on moves in the options market lately.
Can Walgreens' Retail Pharmacy USA Segment Drive Q1 Earnings?
by Zacks Equity Research
Walgreens Boots (WBA) rides high on strength in Retail Pharmacy USA division in fiscal 2017.
Tenet Healthcare Grows on Acquisitions, Lower Revenues Hurt
by Zacks Equity Research
Tenet Healthcare (THC) gains from buyouts, divestitures and strategic initiatives. However, fall in revenues and high level of debt continue to bother.
UnitedHealth (UNH) Arm to Buy Chilean Company for $2.8B
by Zacks Equity Research
UnitedHealth (UNH) is set to buy Empresas Banmedica in order to expand its international operations.
Humana-Kindred Deal Keeps Shakeout Alive in Healthcare Space
by Zacks Equity Research
Humana's (HUM) agreement to acquire Kindred at Home aligns with its strategy to grow vertically.
6 MedTech Stocks Set to Crush the Market in 2018
by Zacks Equity Research
Here we take a peek at six MedTech stocks that are expected to post stellar returns in 2018.
CVS Health Banks on Solid Pharmacy Services, Competition Rife
by Zacks Equity Research
CVS Health's (CVS) strong 2018 PBM selling season buoys optimism.
PBM Industry Shows Strength: 3 Stocks in Focus
by Zacks Equity Research
Consider these three stocks for grand returns from the high-potential PBM market.
CVS-Aetna Deal Leading a Wave of Change in Hospital Sector
by Zacks Equity Research
Increased consolidation is being witnessed in the hospital sector as a defense against invasion by new comers.
Discount Retail Stocks, LULU Earnings, & Healthcare Consolidation
by Ryan McQueeney
On today's episode of the Zacks Friday Finish Line, Content Writer Ryan McQueeney and Editor Maddy Johnson take on this week's biggest stories, including the latest earnings results from Dollar General (DG) and Lululemon (LULU), as well as major healthcare M&A deals involving CVS (CVS), Aetna (AET), and UnitedHealth (UNH).
The Zacks Analyst Blog Highlights: Aetna, CareDx, PRA Health Sciences and Diplomat Pharmacy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Aetna, CareDx, PRA Health Sciences and Diplomat Pharmacy
UnitedHealth to Buy DaVita Medical, Expands Optum Business
by Zacks Equity Research
UnitedHealth's (UNH) intention to buy DaVita Medical reflects its continuous effort to build up a vertically integrated business model
4 Attractive Stocks to Buy in an Evolving Healthcare Space
by Zacks Equity Research
The evolving healthcare industry presents an attractive buying opportunity for investors.